Literature DB >> 9090705

Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity.

M Kågedahl1, P W Swaan, C T Redemann, M Tang, C S Craik, F C Szoka, S Oie.   

Abstract

PURPOSE: To investigate the ability of the human intestinal bile acid transporter to transport cholic acid conjugates with potential HIV-1 protease inhibitory activity.
METHODS: Cholic acid was conjugated at the 24 position of the sterol nucleus with various amino acids and amino acid analogs. The CaCo-2 cell line was used as a model to investigate the interaction of these bile acid conjugates with the human intestinal bile acid transporter. Interaction between the carrier and the conjugates was quantified by inhibition of taurocholic acid transport and confirmed by transport of radiolabelled conjugates in this cell line.
RESULTS: The highest interaction with the transporter, as quantified by inhibition of taurocholic acid transport, occurred when a single negative charge was present around the 24 to 29 region of the sterol nucleus. A second negative charge or a positive charge significantly reduced the interaction. Transport of radiolabelled cholyl-L-Lys-epsilon-tBOC ester and cholyl-D-Asp-beta-benzyl ester was inhibited by taurocholic acid. Of all tested compounds, only cholyl-D-Asp-beta-benzyl ester showed modest HIV-1 protease inhibitory activity with an IC50 of 125 microM.
CONCLUSIONS: Cholic acid-amino acid conjugates with appropriate stereochemistry are recognized and transported by the human bile acid transporter and show modest HIV-1 protease inhibitory activity. Transport of these conjugates by the bile acid carrier is influenced by charge and hydrophobicity around the 24 position of the sterol nucleus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9090705     DOI: 10.1023/a:1012044526054

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  10 in total

1.  Evaluation of the bile acid transporter in enhancing intestinal permeability to renin-inhibitory peptides.

Authors:  D C Kim; A W Harrison; M J Ruwart; K F Wilkinson; J F Fisher; I J Hidalgo; R T Borchardt
Journal:  J Drug Target       Date:  1993       Impact factor: 5.121

2.  Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease.

Authors:  R L DesJarlais; G L Seibel; I D Kuntz; P S Furth; J C Alvarez; P R Ortiz de Montellano; D L DeCamp; L M Babé; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

3.  Transport of bile acids in a human intestinal epithelial cell line, Caco-2.

Authors:  I J Hidalgo; R T Borchardt
Journal:  Biochim Biophys Acta       Date:  1990-07-20

4.  Liver-specific drug targeting by coupling to bile acids.

Authors:  W Kramer; G Wess; G Schubert; M Bickel; F Girbig; U Gutjahr; S Kowalewski; K H Baringhaus; A Enhsen; H Glombik
Journal:  J Biol Chem       Date:  1992-09-15       Impact factor: 5.157

5.  Transepithelial transport of cholyltaurine by Caco-2 cell monolayers is sodium dependent.

Authors:  C E Chandler; L M Zaccaro; J B Moberly
Journal:  Am J Physiol       Date:  1993-06

6.  Bile acid active and passive ileal transport in the rabbit: effect of luminal stirring.

Authors:  R Aldini; A Roda; P L Lenzi; G Ussia; M C Vaccari; G Mazzella; D Festi; F Bazzoli; G Galletti; S Casanova
Journal:  Eur J Clin Invest       Date:  1992-11       Impact factor: 4.686

7.  Positional requirements for anionic charge for ileal absorption of bile salt analogues.

Authors:  L Lack; A Tantawi; C Halevy; D Rockett
Journal:  Am J Physiol       Date:  1984-06

8.  Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption.

Authors:  N F Ho
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

9.  Intestinal absorption of peptides by coupling to bile acids.

Authors:  W Kramer; G Wess; G Neckermann; G Schubert; J Fink; F Girbig; U Gutjahr; S Kowalewski; K H Baringhaus; G Böger
Journal:  J Biol Chem       Date:  1994-04-08       Impact factor: 5.157

10.  Bile acid derived HMG-CoA reductase inhibitors.

Authors:  W Kramer; G Wess; A Enhsen; K Bock; E Falk; A Hoffmann; G Neckermann; D Gantz; S Schulz; L Nickau
Journal:  Biochim Biophys Acta       Date:  1994-11-29
  10 in total
  11 in total

Review 1.  Bile acid transporter-mediated oral drug delivery.

Authors:  Feiyang Deng; You Han Bae
Journal:  J Control Release       Date:  2020-07-22       Impact factor: 9.776

2.  Molecular modeling of the intestinal bile acid carrier: a comparative molecular field analysis study.

Authors:  P W Swaan; F C Szoka; S Oie
Journal:  J Comput Aided Mol Des       Date:  1997-11       Impact factor: 3.686

3.  Transmembrane helix 1 contributes to substrate translocation and protein stability of bile acid transporter SLC10A2.

Authors:  Tatiana Claro da Silva; Naissan Hussainzada; Chandra M Khantwal; James E Polli; Peter W Swaan
Journal:  J Biol Chem       Date:  2011-06-06       Impact factor: 5.157

4.  Structural requirements of the ASBT by 3D-QSAR analysis using aminopyridine conjugates of chenodeoxycholic acid.

Authors:  Xiaowan Zheng; Yongmei Pan; Chayan Acharya; Peter W Swaan; James E Polli
Journal:  Bioconjug Chem       Date:  2010-10-22       Impact factor: 4.774

5.  Interaction of native bile acids with human apical sodium-dependent bile acid transporter (hASBT): influence of steroidal hydroxylation pattern and C-24 conjugation.

Authors:  Anand Balakrishnan; Stephen A Wring; James E Polli
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

Review 6.  Role of the intestinal bile acid transporters in bile acid and drug disposition.

Authors:  Paul A Dawson
Journal:  Handb Exp Pharmacol       Date:  2011

Review 7.  Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target.

Authors:  Anand Balakrishnan; James E Polli
Journal:  Mol Pharm       Date:  2006 May-Jun       Impact factor: 4.939

8.  Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT).

Authors:  Anand Balakrishnan; Daniel J Sussman; James E Polli
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

Review 9.  Exploitation of bile acid transport systems in prodrug design.

Authors:  Elina Sievänen
Journal:  Molecules       Date:  2007-08-16       Impact factor: 4.411

10.  Transmembrane domain V plays a stabilizing role in the function of human bile acid transporter SLC10A2.

Authors:  Robyn H Moore; Paresh Chothe; Peter W Swaan
Journal:  Biochemistry       Date:  2013-07-16       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.